Published in Drug Des Devel Ther on January 07, 2015
Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther (2015) 0.99
Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells. Drug Des Devel Ther (2015) 0.91
Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther (2015) 0.84
Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. Drug Des Devel Ther (2015) 0.78
A SILAC-based proteomics elicits the molecular interactome of alisertib (MLN8237) in human erythroleukemia K562 cells. Am J Transl Res (2015) 0.77
Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. Drug Des Devel Ther (2015) 0.77
Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells. Drug Des Devel Ther (2015) 0.76
DPDR-CPI, a server that predicts Drug Positioning and Drug Repositioning via Chemical-Protein Interactome. Sci Rep (2016) 0.75
Alisertib induces G2/M arrest, apoptosis, and autophagy via PI3K/Akt/mTOR- and p38 MAPK-mediated pathways in human glioblastoma cells. Am J Transl Res (2017) 0.75
Biosynthesis and molecular actions of specialized 1,4-naphthoquinone natural products produced by horticultural plants. Hortic Res (2016) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
mTOR signaling in growth control and disease. Cell (2012) 29.21
The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol (2007) 16.46
Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin (2014) 11.09
Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol (2014) 10.04
Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol (1979) 6.96
The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. J Med Chem (2004) 6.50
Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol (2006) 6.25
A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc (2006) 5.21
Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (2012) 4.76
Targeting mitochondria for cancer therapy. Nat Rev Drug Discov (2010) 4.07
Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol (2013) 3.73
Proteomic applications for the early detection of cancer. Nat Rev Cancer (2003) 3.61
Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol (2013) 3.13
Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem (2001) 2.80
mTOR signaling and drug development in cancer. Nat Rev Clin Oncol (2010) 2.77
New biomarkers in prostate cancer. Oncology (Williston Park) (2014) 2.22
Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs (2005) 2.09
p21WAF1 and tumourigenesis: 20 years after. Curr Opin Oncol (2013) 2.06
Quantitative cancer proteomics: stable isotope labeling with amino acids in cell culture (SILAC) as a tool for prostate cancer research. Mol Cell Proteomics (2004) 2.00
Apoptosis: target of cancer therapy. Clin Cancer Res (2002) 1.99
Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol Biol (2007) 1.96
Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol (2010) 1.80
SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene (2012) 1.70
Epithelial-mesenchymal transition: from molecular mechanisms, redox regulation to implications in human health and disease. Antioxid Redox Signal (2010) 1.68
Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone) induces apoptosis and cell cycle arrest in A549 cells through p53 accumulation via c-Jun NH2-terminal kinase-mediated phosphorylation at serine 15 in vitro and in vivo. J Pharmacol Exp Ther (2006) 1.67
The autophagic paradox in cancer therapy. Oncogene (2011) 1.61
Multilayer control of the EMT master regulators. Oncogene (2013) 1.56
Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol (2011) 1.53
Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med (2013) 1.52
Cellular metabolic and autophagic pathways: traffic control by redox signaling. Free Radic Biol Med (2013) 1.46
Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev (2010) 1.44
Another fork in the road--life or death decisions by the tumour suppressor p53. EMBO Rep (2013) 1.43
Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans (2012) 1.41
Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res (2008) 1.39
Plumbagin induces cell cycle arrest and apoptosis through reactive oxygen species/c-Jun N-terminal kinase pathways in human melanoma A375.S2 cells. Cancer Lett (2007) 1.39
Sirtuin catalysis and regulation. J Biol Chem (2012) 1.35
Super-SILAC allows classification of diffuse large B-cell lymphoma subtypes by their protein expression profiles. Mol Cell Proteomics (2012) 1.29
Nuclear apoptosis detection by flow cytometry: influence of endogenous endonucleases. Exp Cell Res (2002) 1.28
Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene (2013) 1.28
The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol (2013) 1.25
Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species. Pharm Res (2008) 1.24
DRAR-CPI: a server for identifying drug repositioning potential and adverse drug reactions via the chemical-protein interactome. Nucleic Acids Res (2011) 1.23
Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Lett (2013) 1.17
Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer. Urol Oncol (2014) 1.16
Autophagy is differentially induced in prostate cancer LNCaP, DU145 and PC-3 cells via distinct splicing profiles of ATG5. Autophagy (2012) 1.16
Free radicals in cross talk between autophagy and apoptosis. Antioxid Redox Signal (2014) 1.13
Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience. Curr Drug Targets (2013) 1.12
SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res (2009) 1.10
Molecular and chemical regulation of the Keap1-Nrf2 signaling pathway. Molecules (2014) 1.08
Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem (2007) 1.06
Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death. Cancer Treat Rev (2013) 1.05
Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet (1998) 1.05
Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo. Leuk Res (2009) 1.02
Sirtuin deacylases: a molecular link between metabolism and immunity. J Leukoc Biol (2013) 1.02
Evidence of chromosomal instability in prostate cancer determined by spectral karyotyping (SKY) and interphase fish analysis. Neoplasia (2001) 1.02
Proteomics profiling of microdissected low- and high-grade prostate tumors identifies Lamin A as a discriminatory biomarker. J Proteome Res (2010) 1.00
Cdc2: a monopotent or pluripotent CDK? Cell Prolif (2011) 0.98
Identifying unexpected therapeutic targets via chemical-protein interactome. PLoS One (2010) 0.97
N-linked glycosylation enrichment for in-depth cell surface proteomics of diffuse large B-cell lymphoma subtypes. Mol Cell Proteomics (2013) 0.95
Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Int J Cancer (2012) 0.95
ROS, autophagy, mitochondria and cancer: Ras, the hidden master? Mitochondrion (2012) 0.95
Plumbagin inhibits TPA-induced MMP-2 and u-PA expressions by reducing binding activities of NF-kappaB and AP-1 via ERK signaling pathway in A549 human lung cancer cells. Mol Cell Biochem (2009) 0.95
Prostate cancer relevant antigens and enzymes for targeted drug delivery. J Control Release (2014) 0.93
Predicting survival for men with clinically localized prostate cancer: what do we need in contemporary practice? Cancer (2008) 0.92
The expanding field of SILAC. Anal Bioanal Chem (2012) 0.90
Antidiabetic effect of plumbagin isolated from Plumbago zeylanica L. root and its effect on GLUT4 translocation in streptozotocin-induced diabetic rats. Food Chem Toxicol (2012) 0.89
Chromosomal analysis of human prostatic adenocarcinoma cell lines. Cancer Res (1980) 0.88
Molecular pathology and prostate cancer therapeutics: from biology to bedside. J Pathol (2014) 0.88
Mass profiling-directed isolation and identification of a stage-specific serologic protein biomarker of advanced prostate cancer. Proteomics (2005) 0.86
Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells. Mutagenesis (2009) 0.86
Prostate cancer: The androgen receptor remains front and centre. Nat Rev Clin Oncol (2013) 0.85
Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis. Cancer Genomics Proteomics (2010) 0.84
Plumbagin treatment leads to apoptosis in human K562 leukemia cells through increased ROS and elevated TRAIL receptor expression. Leuk Res (2011) 0.84
Apoptosis inducing effect of plumbagin on colonic cancer cells depends on expression of COX-2. PLoS One (2011) 0.84
Chromosome identity of human prostate cancer cell lines, PC-3 and PPC-1. Cytogenet Cell Genet (1993) 0.84
The epidemiology and clinical implications of genetic variation in prostate cancer. Urol Clin North Am (2014) 0.82
Plumbagin activates ERK1/2 and Akt via superoxide, Src and PI3-kinase in 3T3-L1 cells. Eur J Pharmacol (2010) 0.82
Prostate cancer: Time for active surveillance of intermediate-risk disease? Nat Rev Urol (2012) 0.81
Global prostate cancer incidence and the migration, settlement, and admixture history of the Northern Europeans. Cancer Epidemiol (2010) 0.80
The combination of plumbagin with androgen withdrawal causes profound regression of prostate tumors in vivo. Prostate (2012) 0.80
Nomogram for predicting survival in men with clinically localized prostate cancer who do not undergo definitive therapy. Nat Clin Pract Urol (2008) 0.79
Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther (2015) 0.99
Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells. Drug Des Devel Ther (2015) 0.92
The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Drug Des Devel Ther (2015) 0.92
Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells. Drug Des Devel Ther (2015) 0.91
Plumbagin induces G2/M arrest, apoptosis, and autophagy via p38 MAPK- and PI3K/Akt/mTOR-mediated pathways in human tongue squamous cell carcinoma cells. Drug Des Devel Ther (2015) 0.90
Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Drug Des Devel Ther (2015) 0.90
An evidence-based update on the pharmacological activities and possible molecular targets of Lycium barbarum polysaccharides. Drug Des Devel Ther (2014) 0.89
Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther (2014) 0.89
Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Drug Des Devel Ther (2015) 0.85
Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. Drug Des Devel Ther (2015) 0.84
Alisertib, an Aurora kinase A inhibitor, induces apoptosis and autophagy but inhibits epithelial to mesenchymal transition in human epithelial ovarian cancer cells. Drug Des Devel Ther (2015) 0.84
Schisandrin B inhibits cell growth and induces cellular apoptosis and autophagy in mouse hepatocytes and macrophages: implications for its hepatotoxicity. Drug Des Devel Ther (2015) 0.81
Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: a bioinformatic and animal study. Drug Des Devel Ther (2014) 0.81
The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells. Drug Des Devel Ther (2015) 0.81
Bardoxolone methyl induces apoptosis and autophagy and inhibits epithelial-to-mesenchymal transition and stemness in esophageal squamous cancer cells. Drug Des Devel Ther (2015) 0.79
Coffee and caffeine potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of the Tau-mediated pathway in N2a/APP cells. Drug Des Devel Ther (2014) 0.79
Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication. Drug Des Devel Ther (2015) 0.79
Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies. Drug Des Devel Ther (2015) 0.78
Schisandra chinensis regulates drug metabolizing enzymes and drug transporters via activation of Nrf2-mediated signaling pathway. Drug Des Devel Ther (2014) 0.77
Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. Drug Des Devel Ther (2015) 0.77
Plumbagin suppresses epithelial to mesenchymal transition and stemness via inhibiting Nrf2-mediated signaling pathway in human tongue squamous cell carcinoma cells. Drug Des Devel Ther (2015) 0.76